tiprankstipranks
Advertisement
Advertisement

AZN Stock Latest News

AstraZeneca’s ASCEND Obesity Trial Completion Puts New Weight Loss Combo in Focus
Company AnnouncementsAstraZeneca’s ASCEND Obesity Trial Completion Puts New Weight Loss Combo in Focus
24h ago
AZN
AstraZeneca: Late-Stage Pipeline Strength and Lung Cancer Upside Support Buy Rating and Unchanged 16,500 GBp Price Target
PremiumRatings
AstraZeneca: Late-Stage Pipeline Strength and Lung Cancer Upside Support Buy Rating and Unchanged 16,500 GBp Price Target
1d ago
AZN
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
2d ago
AZN
BMY
AstraZeneca announces additional results from Phase III Serena-6 trial
PremiumThe Fly
AstraZeneca announces additional results from Phase III Serena-6 trial
2d ago
AZN
AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial
PremiumThe Fly
AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial
2d ago
AZN
AstraZeneca Adds Employee Scheme Shares to London Listing
PremiumCompany AnnouncementsAstraZeneca Adds Employee Scheme Shares to London Listing
3d ago
AZN
AstraZeneca Confirms Total Voting Rights at 1.55 Billion Shares
Premium
Company Announcements
AstraZeneca Confirms Total Voting Rights at 1.55 Billion Shares
3d ago
AZN
AIM ImmunoTech enrolls final subject in pancreatic cancer development program
Premium
The Fly
AIM ImmunoTech enrolls final subject in pancreatic cancer development program
3d ago
AIM
AZN
AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi
PremiumThe Fly
AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi
3d ago
AZN
Analyst Reiterates Buy on AstraZeneca, Citing Dominant Oncology Portfolio and Sustained Growth Prospects
PremiumRatings
Analyst Reiterates Buy on AstraZeneca, Citing Dominant Oncology Portfolio and Sustained Growth Prospects
3d ago
AZN
AstraZeneca Prostate Cancer Study in Russia Paused, Nudging Real‑World Data Timeline
PremiumCompany Announcements
AstraZeneca Prostate Cancer Study in Russia Paused, Nudging Real‑World Data Timeline
6d ago
AZN
AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint
PremiumThe Fly
AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint
6d ago
AZN
AstraZeneca Imfinzi combination approved in the U.S.
PremiumThe FlyAstraZeneca Imfinzi combination approved in the U.S.
6d ago
AZN
AstraZeneca Wins First U.S. Immunotherapy Combo Approval in Early Bladder Cancer
Premium
Company Announcements
AstraZeneca Wins First U.S. Immunotherapy Combo Approval in Early Bladder Cancer
6d ago
AZN
AstraZeneca’s durvalumab approved in U.S. for NMIBC patients
Premium
The Fly
AstraZeneca’s durvalumab approved in U.S. for NMIBC patients
7d ago
AZN
AstraZeneca confirms FDA approves Imfinzi combo for bladder cancer
PremiumThe Fly
AstraZeneca confirms FDA approves Imfinzi combo for bladder cancer
7d ago
AZN
FDA approves durvalumab combo for high-risk non-muscle invasive bladder cancer
PremiumThe Fly
FDA approves durvalumab combo for high-risk non-muscle invasive bladder cancer
7d ago
AZN
AstraZeneca Bolsters Ovarian Cancer Strategy With Fresh Real-World Study Update
PremiumCompany Announcements
AstraZeneca Bolsters Ovarian Cancer Strategy With Fresh Real-World Study Update
7d ago
AZN
CDT Equity granted Canadian patent for AZD5904 in male infertility
PremiumThe Fly
CDT Equity granted Canadian patent for AZD5904 in male infertility
8d ago
AZN
CDT
AstraZeneca says FDA extends PDUFA date to review camizestrant data for NDA
PremiumThe FlyAstraZeneca says FDA extends PDUFA date to review camizestrant data for NDA
8d ago
AZN
FDA Extends Decision Timeline on AstraZeneca’s Camizestrant Breast Cancer Filing
Premium
Company Announcements
FDA Extends Decision Timeline on AstraZeneca’s Camizestrant Breast Cancer Filing
8d ago
AZN
AstraZeneca: Buy Rating Reiterated on Undervalued Growth Outlook and Late-Stage Pipeline Upside; 16,500 GBp Price Target Maintained
Premium
Ratings
AstraZeneca: Buy Rating Reiterated on Undervalued Growth Outlook and Late-Stage Pipeline Upside; 16,500 GBp Price Target Maintained
9d ago
AZN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >